Sex-steroid regulation of vascular endothelial growth factor in breast cancer

Endocrine-Related Cancer

Volumn 13, Issue 3, 2006, Pages 667-687

  Hyder, S M ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; SEX HORMONE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; BLOOD VESSEL; BREAST CANCER; CHEMOPROPHYLAXIS; HORMONE RESISTANCE; HUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADAL STEROID HORMONES; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33751101135     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00931     Document Type: Review

References (212)

1. Ader DN, South-Paul J, Adera T & Deutser PA 2001 Cyclical mastalgia: prevalence and associated health and behavioral factors. Journal of Psychosomatic Obstetrics and Gynaecology 22 71-76.
2. Akiri G, Nahari D, Finkelstein Y, Le SY, Elroy-Stein O & Levi BZ 1998 Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 17 227-236.
3. Anan K, Morisaki T, Katano M, Ibuko A, Kitsuki H, Uchiyama A, Kuroki S, Tanaka M & Torisu M 1996 Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 119 333-339.
4. Anderson TJ, Ferguson DJ & Raab GM 1982 Cell turnover in the 'resting' human breast: influence of parity, contraceptive pill, age and laterality. British Journal of Cancer 46 376-382.
5. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH & Tosato G 1995 Human interferon inducible protein 10 is a potent inhibitor of angiogenesis in vivo. Journal of Experimental Medicine 182 155-162.
6. Armstrong LC & Bornstein P 2003 Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biology 22 63-71.
7. Aronica SM, Fanti P, Kaminskaya K, Gibbs K, Raiber L, Nazareth M, Bucelli R, Mineo M, Grzybek K, Kumin M et al. 2004 Estrogen disrupts chemokine-mediated chemokine release from mammary cells: implications for the interplay between estrogen and IP-10 in the regulation of mammary tumor formation. Breast Cancer Research and Treatment 84 235-245.
8. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbicher N, Schnatteman G & Isner JM 1997 Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 964-967.
9. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M & Isner JM 1999 VEGF contributes to post natal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO Journal 18 3964-3972.
10. Atqur-Rehman MA & Toi M 2003 Anti-angiogenic therapy in breast cancer. Biomedicine and Pharmacotherapy 57 463-470.
11. Augustin HG 2005 Angiogenesis in the female reproductive system. EXS 94 35-52.
12. Ballare C, Uhrig M, Bechtold T, Sancho E, Domenico MD, Migliaccio A, Auricchio F & Beaot M 2003 Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-src/Erk pathway in mammalian cells. Molecular and Cellular Biology 23 1994-2008.
13. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A & Marme D 1996 Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGT receptor flt-1. Blood 87 3336-3343.
14. Benakanakere I, Besch-Williford C, Schnell JD & Hyder SM 2005 Natural and synthetic progestins accelerate tumor development and increase VEGF production in a chemically induced mammary tumor model: a potentially novel target for anti-angiogenic therapeutics. AACR Special Conference in Advances in Breast Cancer, San Diego, CA. Abstract A15.
15. Bergers G & Benjamin LE 2003 Tumorigenesis and the angiogenic switch. Nature Reviews Cancer 3 401-410.
16. Bermont L, Lamielle-Musard F, Chezy E, Weisz A & Adessi GL 2001 17β-estradiol inhibits forskolin-induced vascular endothelial growth factor promoter in MCF-7 breast adenocarcinoma cells. Journal of Steroid Biochemistry and Molecular Biology 78 343-349.
17. Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T & Neckers L 1998 p53 inhibits hypoxia-inducible factor-stimulated transcription. Journal of Biological Chemistry 273 11995-11998.
18. Bogin L & Degani H 2002 Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer. Cancer Research 62 1948-1951.
19. Borgstrom P, Gold DP, Hillan KJ & Ferrara N 1999 Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Research 19 4203-4214.
20. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ & van der Wall E 2001 Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. Journal of the National Cancer Institute 93 309-314.
21. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P & van der Wall E 2005 Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 46 31-36.
22. Brem SS, Gullino PM & Medina D 1977 Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 195 880-882.
23. Brenner RM & Slayden OD 1994 Cyclic changes in the primate oviduct and endometrium. In The Physiology of Reproduction, vol 1, pp 541-569. Eds E Knobil & JD Neill. New York: Raven Press.
24. Brown LF, Berse B, Jackman RW, Toguazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL & Schnitt SJ 1995 Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Human Pathology 26 86-91.
25. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J & Perrot-Applanat M 2002 Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Research 62 4977-4984.
26. Capillo M, Mancuso P, Gobbi A, Monestirolo G, Pruneri G, Del'Agnola C, Martinelli G, Shultz L & Bertolini F 2003 Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clinical Cancer Research 9 377-382.
27. Carmeliet P 2005 Angiogenesis in life, disease, and medicine. Nature 438 932-936.
28. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD & Colditz GA 2004 Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 101 1490-1500.
29. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA et al. 2003 Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. Journal of the American Medical Association 289 3243-3253.
30. Clarke R, Leonessa F, Welch JN & Skaar TC 2001 Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacological Reviews 53 25-71.
31. Colacurci N, Foraro F, DeFranciscis P, Palermo M & del Vecchio W 2001 Effects of different types of hormone replacement therapy on mammographic density. Maturitas 40 159-164.
32. Connelly OM, Jericevic BM & Lydon JP 2003 Progesterone receptors in mammary gland development and tumorigenesis. Journal of Mammary Gland Biology and Neoplasia 8 205-214.
33. Coradini D, Pellizzaro C, Speranza A & Daidone MG 2004 Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens. Cellular and Molecular Life Sciences 61 76-82.
34. Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z, Ramoner R, Zhang J, Bartsch G, Reissigl A, Radmayr C et al. 1997 Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 31 223-233.
35. Cullinan-Bove K & Koos RD 1993 Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 133 829-837.
36. Dabrosin C 2003 Variability of vascular endothelial normal human breast tissue in vivo during the menstrual cycle. Journal of Clinical Endocrinology and Metabolism 88 2695-2698.
37. Dabrosin C 2005a Sex steroid regulation of angiogenesis in breast tissue. Angiogenesis 8 127-136.
38. Dabrosin C 2005b Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo. Clinical Cancer Research 11 8036-8041.
39. Dabrosin C, Margetts PJ & Gauldie J 2003a Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer. International Journal of Cancer 107 535-540.
40. Dabrosin C, Palmer K, Muller WJ & Gauldie J 2003b Estradiol promotes growth and an giogenesis in polyoma middle T transgenic mouse mammary tumor explants. Breast Cancer Research and Treatment 78 1-6.
41. De Fatta RJ, Turbat-Herrera EA, Li BD, Anderson W & De Benedetti A 1999 Elevated expression of eIF4E in confined early breast cancer lesions: possible role of hypoxia. International Journal of Cancer 80 516-522.
42. De Larco JE, Wuertz BR, Rosner KA, Erickson SA, Gamache DE, Manivel JC & Furcht LT 2001 A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. American Journal of Pathology 158 639-646.
43. Dias S, Thomas H & Balkwill F 1998 Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. International Journal of Cancer 75 151-157.
44. Dvorak HF, Brown LF, Detmar M & Dvorak AM 1995 Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology 146 1029-1039.
45. Elkin M, Orgel A & Kleinman HK 2004 An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor 1. Journal of the National Cancer Institute 96 875-878.
46. Engels K, Fox SB, Whitehouse RM, Gatter KC & Harris AL 1997a Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. Journal of Pathology 181 207-212.
47. Engels K, Fox SB, Whitehouse RM, Gatter KC & Harris AL 1997b Up-regulation of thymidine phophorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. Journal of Pathology 182 414-420.
48. Erel CT, Esen G, Seyisoglu H, Elter K, Uras C, Ertungealp E & Aksu MF 2001 Mammographic density increase in women receiving different hormone replacement regimens. Maturitas 40 151-157.
49. Eriksson U & Alitalo K 1999 Structure, expression, and receptor-binding properties of novel vascular endothelial growth factors. Current Topics in Microbiology and Immunology 237 41-57.
50. Eskens FALM 2004 Angiogenesis inhibitors in clinical development; where are we now and where are we going? British Journal of Cancer 90 1-7.
51. Ferrara N 1999 Vascular endothelial growth factor: molecular and biological aspects. Current Topics in Microbiology and Immunology 237 1-30.
52. Ferrara N 2004a Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 2-10.
53. Ferrara N 2004b Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews 25 581-611.
54. Ferrara N 2005 The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 94 209-231.
55. Ferrara N & Davis-Smyth T 1997 The biology of vascular endothelial growth factor. Endocrinology Reviews 18 4-25.
56. Ferrara N & Kerbel RS 2005 Angiogenesis as a therapeutic target. Nature 438 967-974.
57. Ferrara N, Gerber HP & LeCouter J 2003 The biology of VEGF and its receptors. Nature Medicine 9 669-676.
58. Ferrara N, Hillan KJ & Novotny W 2005 Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and Biophysical Research Communications 333 289-291.
59. Findlay JK 1986 Angiogenesis in reproductive tissues. Journal of Endocrinology 111 357-366.
60. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG & Klijn JG 2001 High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Research 61 5407-5414.
61. Folkman J 1995 Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1 27-31.
62. Folkman J 1998 Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology 139 441-442.
63. Folkman J 2003 Fundamental concepts of the angiogenic process. Current Molecular Medicine 3 643-651.
64. Folkman J & Hanahan D 1991 Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symposium 22 339-347.
65. Fox HS, Bond BL & Parslow TG 1991 Estrogen regulates the IFN gamma promoter. Journal of Immunology 146 4362-4367.
66. Garvin S & Dabrosin C 2003 Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Research 63 8742-8748.
67. Garvin S, Nilsson UW & Dabrosin C 2005 Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. British Journal of Cancer 93 1005-1010.
68. Gasparini G 1997 Angiogenesis in endocrine-related cancer. Endocrine-Related Cancer 4 423-445.
69. Gasparini G 2000 Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5 S37-S44.
70. Gasparini G, Toi M, Miceli R, Vermuelen PB, Dittadi R, Biganzoli E, Morabito A, Fanell M, Gatti C, Suzuki H et al. 1999 Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer Journal from Scientific American 5 101-111.
71. Gasparini G, Longo R, Torino F & Morabito A 2005 Therapy of breast cancer with molecular targeting agents. Annals of Oncology 16 (Suppl 4) iv28-iv36.
72. Gimbrone MA Jr & Gullion PM 1976 Angiogenic capacity of preneoplastic lesions of the murine mammary gland as a marker of neoplastic transformation. Cancer Research 36 2611-2620.
73. Goldberg ID & Rosen EM 1997 Regulation of angiogenesis. EXS 79.
74. Greb RR, Heikinheimo O, Williams RF, Hodgen GD & Goodman AL 1997 Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands in vivo. Human Reproduction 12 1280-1292.
75. Guidi AJ, Fischer L, Harris JR & Schnitt SJ 1994 Microvessel density and distribution in ductal carcinoma in situ of the breast. Journal of the National Cancer Institute 86 614-619.
76. Guidi AJ, Schnitt SJ, Fischer L, Tognazzi K, Harris JR, Dvorak HF & Brown LF 1997 Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 15 1945-1953.
77. Guinebretiere JM, LeMonique G, Gavoille A, Bahi J & Contesso G 1994 Angiogenesis and risk of breast cancer in women with fibrocystic disease. Journal of the National Cancer Institute 86 635-636.
78. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK & Dowsett M 2005 Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. Journal of Clinical Oncology 23 2469-2476.
79. Hicklin DJ & Ellis LM 2005 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology 23 1011-1027.
80. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT & De Bruijn EA 2004 Vascular endothelial growth factor and angiogenesis. Pharmacological Review 56 549-580.
81. Huh JI, Calvo A, Stafford J, Cheung M, Kumar R, Philp D, Kleinman HK & Green JE 2004 Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms. Oncogene 24 790-800.
82. Hyder SM 2002 The role of steroid hormones on the regulation of vascular endothelial growth factor. American Journal Pathology 161 345-346.
83. Hyder SM & Stancel GM 1999 Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Molecular Endocrinology 13 806-811.
84. Hyder SM & Stancel GM 2000 Regulation of VEGF in the reproductive tract by sex-steroid hormones. Histology and Histopathology 15 325-334.
85. Hyder SM & Stancel GM 2002 Inhibition of progesterone-induced VEGF production in human breast cancer cells by the pure antiestrogen ICI 182,780. Cancer Letters 181 47-53.
86. Hyder SM, Nawaz Z, Chiappetta C, Yokoyama K & Stancel GM 1995 The protooncogene c-jun contains an unusual estrogen-inducible enhancer within the coding sequence. Journal of Biological Chemistry 270 8506-8513.
87. Hyder SM, Stancel GM, Chiappetta C, Murthy L, Boettger-Tong HL & Makela S 1996 Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Research 56 3954-3960.
88. Hyder SM, Chiappetta C, Murthy L & Stancel GM 1997 Selective inhibition of estrogen-regulated gene expression in vivo by the pure antiestrogen ICI 182,780. Cancer Research 57 2547-2549.
89. Hyder SM, Murthy L & Stancel GM 1998 Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Research 58 392-395.
90. Hyder SM, Nawaz Z, Chiappetta C & Stancel GM 2000a Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Research 60 3183-3190.
91. Hyder SM, Huang JC, Nawaz Z, Boettger-Tong H, Makela S, Chiappetta C & Stancel GM 2000b Regulation of vascular endothelial growth factor expressions by estrogens and progestins. Environmental Health Perspectives 108 785-790.
92. Hyder SM, Chiappetta C & Stancel GM 2001 Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. International Journal of Cancer 92 469-473.
93. Jain R 2005 Normalization of tumor vasculature: an emerging concept in anti-angiogenic therapy. Science 307 58-62.
94. Jain RK, Duda DG, Clark JW & Loeffler JS 2006 Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clinical Practice & Oncology 3 24-40.
95. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K 1997. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276 1423-1425. Erratum in: Science 277 463.
96. Jensen HM, Chen I, DeVault MF & Lewis AE 1982 Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer. Science 218 293-295.
97. de Jong JS, van Diest PJ, van der Valk P & Baak JP 1998 Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. Journal of Pathology 184 44-52.
98. Kaklamani VG & Gradishar WJ 2005 Adjuvant therapy of breast cancer. Cancer Investigation 23 548-560.
99. Kazi AA, Jones JM & Koos RD 2005 Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypoxia inducible factor 1 to the vascular endothelial growth factor promoter. Molecular Endocrinology 19 2006-2019.
100. Kevil CG, De Benedetti A, Payne DK, Coe LL, Laroux FS & Alexander JS 1996 Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. International Journal of Cancer 65 785-790.
101. Khalkhali-Ellis Z, Christian AL, Kirschmann DA, Edwards EM, Rezaie-Thompson M, Vasef MA, Gruman LM, Seftor RE, Norwood LE & Hendrix MJ 2004 Regulating the tumor suppressor gene maspin in breast cancer cells: a potential mechanism for the anticancer properties of tamoxifen. Clinical Cancer Research 10 449-454.
102. Koga K, Osuga Y, Yoshino O, Hirota Y, Fuimeng X, Hirata T, Takea S, Yano T, Tsutmi O & Taketami Y 2003 Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. Journal of Clinical Endocrinology and Metabolism 88 2348-2351.
103. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascer TG, Paulweber B, Haas J & Samonigg H 2003 A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. International Journal of Cancer 106 468-471.
104. Krippl P, Langsenlehner U, Samonigg H, Renner W & Koppel H 2004 Vascular endothelial growth factor in predicting outcome in breast cancer. Clinical Cancer Research 10 8752-8753.
105. Kucab JE & Dunn SE 2003 Role of IGF-1R in mediating breast cancer invasion and metastasis. Breast Disease 17 41-47.
106. Kurebayashi J, Otsuki T, Moriya T & Sonoo H 2001 Hypoxia reduces hormone responsiveness of human breast cancer cells. Japanese Journal of Cancer Research 92 1093-1101.
107. Lanari C & Molinolo A 2002 Progesterone receptors-animal models and cell signaling in breast cancer, diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer. Breast Cancer Research 4 240-243.
108. Lee AH, Dublin EA, Bobrow LG & Poulsom R 1998 Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. Journal of Pathology 185 394-401.
109. Lee HJ, Cho CH, Hwang SJ, Choi HH, Kim KT, Ahn Sy, On JL, Lee GM & Koh GY 2004 Biological characterization of angiopoietin-3 and angiopoietin-4. FASEB Journal 18 1200-1208.
110. Liang Y & Hyder SM 2005 Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects. Endocrinology 146 3632-3641.
111. Liang Y, Wu J & Hyder SM 2005 p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 93 173-182.
112. Lichtenbeld HC, Barendsz-Janson AF, ven Essen H, Struijker Boudeier H, Griffioen AW & Hillen HF 1998 Angiogenic potential of malignant and non-malignant human breast tissues in an in vivo angiogenesis model. International Journal of Cancer 77 455-459.
113. Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C & Huang RP 2004 Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. International Journal of Cancer 109 507-515.
114. Linderholm B, Travelin B, Grankvist K & Henriksson R 1998 Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. Journal of Clinical Oncology 16 3121-3128.
115. Linderholm B, Lindh B, Tavelin B, Grankvist K & Henriksson R 2000a p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. International Journal of Cancer 89 51-62.
116. Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B & Henriksson R 2000b Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant therapy. Journal of Clinical Oncology 18 1423-1431.
117. Linderholm BK, Lindhal T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R & Bergh J 2001 The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Research 61 2256-2260.
118. Liu Z, Shi HY, Nawaz Z & Zhang M 2004 Tamoxifen induces the expression of maspin through estrogen receptor-alpha. Cancer Letters 209 55-65.
119. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D & Gasparini G 2002 Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 5 237-256.
120. Losordo DW & Isner JM 2001 Estrogen and angiogenesis: a review. Arteriosclerosis Thrombosis and Vascular Biology 21 6-12.
121. Lyden D, Hattori K & Dias S 2001 Impaired recruitment of bone marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Medicine 7 1194-1201.
122. McLeskey SW, Tobias CA, Vezza PR, Filie AC, Kern FG & Hanfelt J 1998 Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor. American Journal of Pathology 153 1993-2006.
123. Maiorana A & Gullino PM 1978 Acquisition of angiogenic capacity and neoplastic transformation in the rat mammary gland. Cancer Research 38 4409-4414.
124. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW & Sonenberg N 2004 eIF4E-from translation to transformation. Oncogene 23 3172-3179.
125. Manders P, Beex LV, Tjan-Heijnen VC, Span PN & Sweep CG 2003 Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer 98 2125-2132.
126. Martin L, Finn CA & Trinder G 1973 Hypertrophy and hyperplasia in the mouse uterus after oestrogen treatment: an autoradiographic study. Journal of Endocrinology 56 133-144.
127. Medina D, Kittrell FS, Shepard A, Contreras A, Rosen JM & Lydon J 2003 Hormone dependence in premalignant mammary progression. Cancer Research 63 1067-1072.
128. Metheny-Barlow LJ & Li LY 2003 The enigmatic role of angiopoietin-1 in tumor angiogenesis. Cell Research 13 309-317.
129. Meunier-Carpentier S, Dales JP, Djemli A, Garcia S, Bonnier P, Andrac-Meyer L, Lavaut MN, Allasia C & Charpin C 2005 Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. International Journal of Oncology 26 977-984.
130. Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Bitner M, Rziha HJ, Dehio C 1999 A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signaling through VEGFR-2 (KDR) but not VEGFR-1 (Fit-1) receptor tyrosine kinases. EMBO Journal 18 363-374.
131. Milanini-Mongiat J, Pouyssegur J & Pages G 2002 Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. Journal of Biological Chemistry 277 20631-20639.
132. Mirkin S & Archer DF 2004 Effects of mifepristone on vascular endothelial growth factor and thrombospondi-1 mRNA in Ishikawa cells: implications for endometrial effects of mifepristone. Contraception 70 327-333.
133. Mirkin S, Wong BC & Archer DF 2005 Effect of 17β-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertility and Sterility 84 485-491.
134. Mohsin SK, Zhang M, Clark GM & Craig Allred D 2003 Maspin expression in invasive breast cancer: association with other prognostic factors. Journal of Pathology 199 432-435.
135. Moore MR 2004 A rationale for inhibiting progesterone-related pathways to combat breast cancer. Current Cancer Drug Targets 4 183-189.
136. Morabito A, Sarmiento R, Bonginelli P & Gasparini G 2004 Antiangiogenic strategies, compounds and early clinical results in breast cancer. Critical Reviews in Oncology/Hematology 49 91-107.
137. Moses MA, Harper J & Fernandez CA 2004 A role for antiangiogenic therapy in breast cancer. Current Oncology Report 6 42-48.
138. Mueller MD, Vigne JL, Minchenko A, Lebovie Di, Leitman DC & Taylor RN 2000 Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. PNAS 97 10972-10977.
139. Mueller MD, Vigne JL, Pritts EA, Chao V, Dreher E & Taylor RN 2003 Progestins activate vascular endothelial growth factor gene transcription in endometrial adenocarcinoma cells. Fertility and Sterility 79 386-392.
140. Nakamura J, Savinvov A, Lu Q & Brodie A 1996 Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a) anthracene-induced rat mammary tumors. Endocrinology 137 5589-5596.
141. Nakamura J, Lu Q, Aberdeen G, Albrecht E & Brodie A 1999 The effect of estrogen on aromatase and vascular endothelial growth factor messenger ribonucleic acid in the normal nonhuman primate mammary gland. Journal of Clinical Endocrinology and Metabolism 84 1432-1437.
142. Nakopoulou L, Stefanaki K, Panayotopoulou E, Giannopoulou I, Athanassiadou P, Gakiopoulou-Givalou H & Louvrou A 2002 Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Human Pathology 33 863-870.
143. Nathan CA, Carter P, Liu L, Li BD, Abreo F, Tudor A, Zimmer SG & De Benedetti A 1997 Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene 15 1087-1094.
144. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, Watnick RS, Straume O, Akslen LA, Folkman J et al. 2006 A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype.. Journal of the National Cancer Institue 98 316-325.
145. Navolanic PM & McCubrey JA 2005 Pharmacological breast cancer therapy (review). International Journal of Oncology 27 1341-1344.
146. Neufeld G, Cohen T, Gengrinovitch S & Poltorak Z 1999 Vascular endothelial growth factor (VEGF) and its receptors. FASEB Journal 13 9-22.
147. Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D & Gee JMW 2005 Growth factor signaling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocrine-Related Cancer 12 S29-S36.
148. Nicosia RR & Villaschi S 1999 Autoregulation of angiogenesis by cells of the vessel wall. International Reviews of Cytology 185 1-43.
149. Noh JJ, Maskarinec G, Pagano I, Cheung LW & Stanchyk FZ 2005 Mammographic densities and circulating hormones: a cross-sectional study in premenopausal women. Breast In Press.
150. Ortega N, Hutchings H & Plouet J 1999 Signal relays in the VEGF system. Frontiers of Bioscience 4 141-152.
151. Otsuki M, Saito H, Xu X, Sumitani S, Souhara H, Kishimoto T & Kasayama S 2001 Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arteriosclerosis Thrombosis and Vascular Biology 21 243-248.
152. Pages G & Pouyssegur J 2005 Transcriptional regulation of the vascular endothelial growth factor gene - a concert of activating factors. Cardiovascular Research 65 564-573.
153. Pal S, Claffey KP, Cohen HT & Mukhopadhyay D 1998 Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. Journal of Biological Chemistry 273 26277-26280.
154. Pal S, Datta K & Mukhopadhyay D 2001 Central role of p53 on regulation of vascular permeability factor/ vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Research 61 6952-6957.
155. Pasqualini JR 2000 In Breast Cancer: Prognosis, Treatment and Prevention. New York: Marcel Dekker.
156. Pekala P, Marlow M, Heuvelman D & Connolly D 1990 Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin. Journal of Biological Chemistry 265 18051-18054.
157. Price DJ, Miralem T, Jiang S, Steinberg R & Avraham H 2001 Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth and Differentiation 12 129-135.
158. Rafii S, Lyden D, Benezra R, Hattori K & Heissig B 2002 Vascular and hematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nature Reviews Cancer 2 826-835.
159. Ragaz J, Miller K, Badve S, Dayachko Y, Dunn S, Nielsen T, Brodie A, Huntsman D, Bajdik C et al. 2004 Adverse association of expressed vascular endothelial growth factor (VEGF) Her2, Cox2, uPA, and EMSY with long-term outcome of stage I - III breast cancer (BrCA). Results from the British Columbia Tissue Microarray Project. Proceedings of the American Society of Clinical Oncology 23 8.
160. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D & Kerbel RS 1995 Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Review 14 263-277.
161. Rak J, Filmus J & Kerbel RS 1996 Reciprocal paracrine interactions between tumor cells and endothelial cells: the 'angiogenesis progression' hypothesis. European Journal of Cancer 32 2438-2450.
162. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Lee R, Moghaddam A, Whitehouse R, Bicknell R & Harris AL 1997 Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placental growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Research 57 963-969.
163. Reome JB, Hylind JC, Dutton RW & Dobrazanski MJ 2004 Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer. Clinical Immunology 111 69-81.
164. Reynolds LP, Killilea SD & Redmer DA 1992 Angiogenesis in the female reproductive system. FASEB Journal 6 886-892.
165. Ribatti D, Nico B, Vacca A, Roncali L & Dammacco F 2002 Endothelial cell heterogeneity and organ specificity. Journal of Hematotherapy and Stem Cell Research 11 81-90.
166. Risau W 1997 Mechanisms of angiogenesis. Nature 386 671-674.
167. Roberts WG & Palade GE 1995 Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. Journal of Cellular Sciences 108 2369-2379.
168. Ross RK, Paganini-Hill A, Wan PC & Pike MC 2000 Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. Journal of the National Cancer Institute 92 328-332.
169. Ruhola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K & Harkonene PL 1999 Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Molecular and Cellular Endocrinology 149 29-40.
170. Ryden L, Linderholm B, Nielsen NH, Erndin S, Jonsson PE & Landberg G 2003 Tumor specific VEGF-A and VEGF2/KDR protein are co-expressed in breast cancer. Breast Cancer Research and Treatment 82 147-154.
171. Ryden L, Jirstrom K, Bendahl PO, Ferno M, Nordenskjold B, Stal O, Thorstenson S, Jonsson PE & Landberg G 2005 Tumor specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premeopausal women. Journal of Clinical Oncology 23 4695-4704.
172. Saaristo A, Karpanen T & Alitalo K 2000 Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 19 6122-6129.
173. Sartorius CA, Shen T & Horwitz KB 2003 Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts. Breast Cancer Research and Treatment 79 287-299.
174. Schairer C 2002 Progesterone receptors - animal models and cell signaling in breast cancer, implications for breast cancer of inclusion of progestins in hormone replacement therapies. Breast Cancer Research 4 244-248.
175. Schneider BP & Miller KD 2005 Angiogenesis of breast cancer. Journal of Clinical Oncology 23 1782-1790.
176. Schoeffner DJ, Matheny SL, Akahane T, Factor V, Berry A, Merlino G & Thorgeirsson UP 2005 VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. Laboratory Investigation 85 608-623.
177. Sengupta K, Banerjee S, Saxena H & Banerjee SK 2003 Estradiol-induced vascular endothelial growth factor-A expression in breast tumor cells is biphasic and regulated by estrogen receptor-alpha dependent pathway. International Journal of Oncology 22 609-614.
178. Shao ZM, Radziszewski WJ & Barsky SH 2000 Tamoxifen enhances myoepithelial cell suppression of human breast carcinoma progression in vitro by two different effector mechanisms. Cancer Letters 157 133-144.
179. Shi HY, Zhang W, Liang R, Abraham S, Kittrell FS, Medina D & Zhang M 2001 Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Research 61 6945-6951.
180. Shirakawa K, Furuhata S, Watanabe I, Hayase H, Shimizu A, Ikarashi Y, Yoshida T, Terada M, Hashimoto D et al. 2002a Induction of vasculogenesis in breast cancer models. British Journal of Cancer 87 1454-1461.
181. Shirakawa K, Shibuya M, Heike Y, Takashima S, Watanabe I, Konishi F, Kasumi F, Goldman CK, Thomas KA, Bett A 2002b Tumor-infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer. International Journal of Cancer 99 344-351.
182. Simantov R & Silverstein RL 2003 CD36: a critical anti-angiogenic receptor. Frontiers in Bioscience 8 S874-S882.
183. Sledge GW Jr & Miller KD 2003 Exploiting the hallmarks of cancer: the future conquest of breast cancer. European Journal of Cancer 39 1668-1675.
184. Soderqvist G, Isaksson E, von Schoultz B, Carlstrom K, Tani E & Skoog L 1997 Proliferation of breast epithelial cells in healthy women during the menstrual cycle. American Journal of Obstetrics and Gynecology 176 123-128.
185. Sordello S, Bertrand N & Plouet J 1998 Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochemical and Biophysical Research Communications 251 287-290.
186. Soufla G, Porchis R, Sourvinos G, Vassilaros S & Spandidos DA 2005 Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3, and cognate receptors in breast tumorigenesis. Cancer Letters In Press.
187. Speirs V & Atkin SL 1999 Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumors. British Journal of Cancer 80 898-903.
188. Spring H, Schuler T, Arnold B, Hammerling GJ & Ganss R 2005 Chemokines direct endothelial progenitors into tumor neovessels. PNAS 102 18111-18116.
189. Stevens A, Soden J, Brenchley PE, Ralph S & Ray DW 2003 Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Research 63 812-816.
190. Stoner M, Wormke M, Saville B, Samudio I, Qin C, Abdelrahim M & Safe S 2004 Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins. Oncogene 23 1052-1063.
191. Thomas T, Rhodin J, Clark L & Garces A 2003 Progestins initiate adverse events of menopausal estrogen therapy. Climacteric 6 265-267.
192. Toi M, Hoshina S, Takayanagi T & Tominaga T 1994 Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Japanese Journal of Cancer Research 85 1045-1049.
193. Toi M, Inada K, Hoshina S, Suzuki H, Kondo S & Tominaga T 1995a Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clinical Cancer Research 1 961-964.
194. Toi M, Inada K, Suzuki H & Tominaga T 1995b Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Research and Treatment 36 193-204.
195. Umekita Y, Ohi Y, Sagara Y & Yoshidat I 2002 Expression of maspin predicts poor prognosis in breast-cancer patients. International Journal of Cancer 100 452-455.
196. Uray IP, Liang Y & Hyder SM 2004 Estradiol down regulates CD36 expression in human breast cancer cells. Cancer Letters 20 101-107.
197. Wang TN, Qian XH, Granick MS, Soloman MP, Rothman VL, Berger DH & Tuszynski GP 1996 Inhibition of breast cancer progression by an antibody to thrombospondin-1 receptor. Surgery 120 449-454.
198. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A & Steinberg SM 2006 Antiangiogenic and antitumor effects of bevacizumab in inflammatory and locally advanced breast cancer patients. Journal of Clinical Oncology In Press.
199. Weidner N, Semple JP, Welch WR & Folkman J 1991 Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. New England Journal of Medicine 324 1-8.
200. Weidner N, Folkman J, Pozza F, Bevilacque P, Allred EN, More DH, Meli S & Gasparnini G 1992 Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. Journal of the National Institutes of Cancer 84 1875-1887.
201. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui TG, Sugiono M, Waine E, Perrin R et al. 2004 VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Research 64 7822-7835.
202. Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. Journal of the American Medical Association 288 321-333.
203. Wu J, Richer J, Horwitz KB & Hyder SM 2004 Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Cancer Research 64 2238-2244.
204. Wu J, Brandt S & Hyder SM 2005a Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells. Molecular Endocrinology 19 312-326.
205. Wu J, Liang Y, Nawaz Z & Hyder SM 2005b Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone receptor-B: implications for treatment resistance. International Journal of Oncology 27 1647-1659.
206. Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A & Mori T 1996 Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clinical Cancer Research 2 821-826.
207. Yazidi IE, Renaud F, Laurent M, Courtois Y & Boilly-Marer Y 1998 Production and estrogen regulation of FGF1 in normal and cancer breast cells. Biochimica Biophysica Acta 1403 127-140.
208. Zetter RR 1998 Angiogenesis and tumor metastasis. Annual Reviews in Medicine 49 407-424.
209. Zhang HT, Craft P, Scott PA, Ziche M, Weich HA, Harris AL & Bicknell R 1995 Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. Journal of the National Cancer Institute 87 213-219.
210. Zhang HT, Scott PA, Morbidelli L, Peak S, Moore J, Turley H, Harris AL, Ziche M & Bicknell R 2000a The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. British Journal of Cancer 83 63-68.
211. Zhang M, Volpert O, Shi YH, Peak S, Moor J, Turley H, Harris AL, Ziche M & Bicknell R 2000b Maspin is an angiogenesis inhibitor. Nature Medicine 6 196-199.
212. Zhang W, Ran S, Sambade M, Huang X & Thorpe PE 2002 A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 5 35-44.